Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties

Over the past decade, CAR T cell therapy for patients with B cell malignancies has evolved from an experimental technique to a clinically feasible option. To date, four CAR T cell products specific for a B cell surface marker, CD19, have been approved by the FDA. Despite the spectacular rates of com...

Descripción completa

Detalles Bibliográficos
Autores principales: Belovezhets, Tatyana, Kulemzin, Sergey, Volkova, Olga, Najakshin, Alexander, Taranin, Alexander, Gorchakov, Andrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966244/
https://www.ncbi.nlm.nih.gov/pubmed/36835110
http://dx.doi.org/10.3390/ijms24043698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966244/
https://www.ncbi.nlm.nih.gov/pubmed/36835110
http://dx.doi.org/10.3390/ijms24043698

Ejemplares similares